CBX8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30315936	1.00	4/20
SCHEMBL29613505	0.91	4/20
SCHEMBL27223064	0.89	4/20
SCHEMBL27232005	0.89	4/20
SCHEMBL23682719	0.87	4/20
SCHEMBL23682865	0.87	4/20
SCHEMBL23717921	0.87	4/20
SCHEMBL23718040	0.87	4/20
SCHEMBL26219950	0.87	4/20
SCHEMBL23682648	0.80	4/20
SCHEMBL23682893	0.80	4/20
SCHEMBL29613457	0.79	4/20
SCHEMBL23683125	0.79	4/20
SCHEMBL23815561	0.78	4/20
SCHEMBL24510752	0.78	4/20
SCHEMBL23718039	0.75	4/20
SCHEMBL23815796	0.75	4/20
SCHEMBL24510878	0.74	4/20
SCHEMBL24510644	0.72	4/20
SCHEMBL23682687	0.72	4/20

Clinical trials — most relevant to CBX8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer	PHASE1/PHASE2	SUSPENDED
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer	PHASE1/PHASE2	WITHDRAWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Patients With RETT Syndrome	nan	UNKNOWN
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
Genetic Investigation of Solid Tumors Cohort	nan	COMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
S9031-S9126-S9333-S9500-A, Studying Bone Marrow and Blood Samples From Patients With Acute Myeloid Leukemia	nan	COMPLETED
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes	nan	ACTIVE_NOT_RECRUITING
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Cause of Familial Testicular Cancer	nan	COMPLETED
Tissue Bank of Biological Specimens From Patients With Gynecologic Disease	nan	UNKNOWN
Familial Investigations of Childhood Cancer Predisposition	nan	RECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies	nan	ACTIVE_NOT_RECRUITING
Immunophenotyping and Xist Gene in AML	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Characterization of At-risk Population for Pre-sacral Tumor in CURRARINO Syndrome	nan	COMPLETED
Genetic Study of Familial Epilepsy	nan	COMPLETED
Clinical and Genomic Registry of MDS in Asia	nan	UNKNOWN
Chromosome 18 Clinical Research Center	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CBX8 binder may also engage these)

Protein	Name	Similarity
Q9QXV1	—	1.000	Q9QXV1 →
Q8BSD5	—	0.990	Q8BSD5 →
CBX4	E3 SUMO-protein ligase CBX4	0.990	landscape →
P97838	—	0.989	P97838 →
Q9DBY5	—	0.989	Q9DBY5 →
O95886	—	0.989	O95886 →
Q6PFD5	—	0.989	Q6PFD5 →
Q5VZ18	—	0.989	Q5VZ18 →
CBX6	Chromobox protein homolog 6	0.988	landscape →
Q9R1Z8	—	0.988	Q9R1Z8 →
Q5TZ18	—	0.988	Q5TZ18 →
Q9P1Z0	—	0.988	Q9P1Z0 →
P53814	—	0.988	P53814 →
Q9Z0Y7	—	0.988	Q9Z0Y7 →
Q9P1A6	—	0.988	Q9P1A6 →
Q76LL6	—	0.988	Q76LL6 →
SETD1A	Histone-lysine N-methyltransferase SETD1A	0.987	landscape →
Q80Z38	—	0.987	Q80Z38 →
B1AZP2	—	0.987	B1AZP2 →
Q80WT2	—	0.987	Q80WT2 →
Q66J90	—	0.987	Q66J90 →
Q2PFD7	—	0.987	Q2PFD7 →
Q80TZ9	—	0.987	Q80TZ9 →
Q96IZ0	—	0.987	Q96IZ0 →
Q6PEI3	—	0.987	Q6PEI3 →
Q3UHD9	—	0.987	Q3UHD9 →
D6RIA3	—	0.987	D6RIA3 →
P21999	—	0.987	P21999 →
SETD1B	Histone-lysine N-methyltransferase SETD1B	0.987	landscape →
TET3	Methylcytosine dioxygenase TET3	0.987	landscape →